Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Lucentis Wet AMD Growth May Cool In 2007, Genentech Says

This article was originally published in The Pink Sheet Daily

Executive Summary

Rapid uptake seen in 2006 is likely to level off this year as patients transition to lower dose frequency, according to the firm.

You may also be interested in...



Genentech Moves To Dampen Avastin Use In Wet AMD By Limiting Sales To Compounding Pharmacists

As of Nov. 30, Avastin can no longer be purchased by compounding pharmacists from wholesale distributors, company announces in "Dear Retinal Community Member" letter.

Genentech Moves To Dampen Avastin Use In Wet AMD By Limiting Sales To Compounding Pharmacists

As of Nov. 30, Avastin can no longer be purchased by compounding pharmacists from wholesale distributors, company announces in "Dear Retinal Community Member" letter.

Herceptin Adjuvant Breast Cancer Sales Slow In First Quarter

Genentech eyes additional opportunities for trastuzumab in adjuvant setting in node-positive, hormone receptor-positive breast cancer patients.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS065000

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel